Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Cell Transplant ; 33: 9636897231219733, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38173231

RESUMEN

Low back pain (LBP) is a leading cause of long-term disability globally. Intervertebral disk degeneration (IVDD) is mainly responsible for discogenic pain in LBP-affected young patients. There is no effective therapy to reverse disease severity and IVDD progression. This study investigates the effect of human peripheral blood-derived mononuclear cells (PBMCs) on pain relief and life quality improvement in IVDD patients. The enriched monocytes of the PBMCs could differentiate into CD14 and CD206 double-positive M2 macrophages in vitro. Preclinical evidence in rats showed that the transplanted PBMCs exhibited anti-inflammatory and moderate tissue-repair effects on controlling IVDD progress in the rat model. The PBMCs significantly steered the aggrecan and type II collagen expressions and attenuated the pro-inflammatory cytokines in the affected disk. Based on the animal results, 36 patients with chronic low back pain (CLBP) were included in clinical trials. The control group was conservative care only, and the experimental group was platelet-rich plasma (PRP) and PBMCs intradiscal injections. We first confirmed the single lumbar disk causing the discogenic pain by provocative discography or magnetic resonance imaging (MRI). Discogenic LBP participants received one intradiscal injection of autologous PBMCs and followed for 6 months. Our clinical trial showed that patients' LBP and disability were significantly ameliorated after the PBMCs transplantation rather than PRP. These preclinical and pilot clinical studies indicate that intradiscal injection of the enriched PBMCs might be a feasible and potential cell therapy to control pain and disability in IVDD patients.


Asunto(s)
Degeneración del Disco Intervertebral , Disco Intervertebral , Dolor de la Región Lumbar , Humanos , Animales , Ratas , Degeneración del Disco Intervertebral/terapia , Disco Intervertebral/patología , Dolor de la Región Lumbar/tratamiento farmacológico , Dolor de la Región Lumbar/etiología , Inyecciones/efectos adversos , Antiinflamatorios/farmacología , Resultado del Tratamiento
2.
Cell Transplant ; 32: 9636897221149445, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36661223

RESUMEN

Osteoarthritis (OA) is a common chronic skeletal disease in the elderly. There is no effective therapy to reverse disease severity and knee OA (KOA) progression, particularly at the late stage. This study aims to examine the effect of peripheral blood-derived mononuclear cells (PBMNCs) on pain and motor function rescue in patients with Kellgren-Lawrence (KL) grade II to IV KOA. Participants received one intra-articular (IA) injection of autologous PBMNCs. The mononuclear cells were isolated from peripheral blood, enriched by a specialized medium (MoFi medium), and separated by Ficoll-Paque solution. The isolated and enriched PBMNCs could differentiate into M1 and M2 macrophages in vitro. The in vivo anti-inflammatory effect of the PBMNCs was similar to that of bone marrow mesenchymal stem cells, evaluated by complete Freund's adjuvant-induced arthritis in rodents. A single-arm and open-label pilot study showed that patients' knee pain and motor dysfunction were significantly attenuated after the cell transplantation, assessed by visual analogue scale (VAS) and Knee injury and Osteoarthritis Outcome Score (KOOS) at 6 and 12 months post-treatment. Notably, the therapeutic effect of the PBMNCs treatment can be stably maintained for 24 months, as revealed by the KOOS scores. These preclinical and pilot clinical data suggest that IA injection of MoFi-PBMNCs might serve as a novel medical technology to control the pain and the progress of KOA.


Asunto(s)
Osteoartritis de la Rodilla , Humanos , Osteoartritis de la Rodilla/terapia , Proyectos Piloto , Resultado del Tratamiento , Articulación de la Rodilla , Inyecciones Intraarticulares , Dolor/tratamiento farmacológico
3.
Sci Rep ; 12(1): 21663, 2022 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-36522405

RESUMEN

The human type II collagen (Col II), specifically expressed in chondrocytes, is a crucial component of the adult hyaline cartilage. We examine the potential of artificial induction of Col II in human peripheral blood mononuclear cells (PBMNCs) as a novel Col II provider. Human PBMNCs were purified and were treated with high doses of macrophage-colony stimulating factor (M-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), or granulocyte-colony stimulating factor (G-CSF) and examined the Col II expression at indicated days. Quantitative Col II expression was validated by real-time reverse transcriptase-polymerase chain reaction (RT-PCR), immunocytochemistry, and flow cytometry. We demonstrate that monocytes in PBMNCs can be artificially induced to express both Col II proteins and M2 macrophage markers by the high concentration of colony-stimulating factors, especially M-CSF and GM-CSF. The Col II proteins were detected on the cell membrane and in the cytoplasm by flow cytometry and immunocytostaining. Combination with IL-4 provided a synergistic effect with M-CSF/GM-CSF to trigger Col II expression in M2 macrophages. These CD206 and Col II double-expressing cells, named modified macrophages, share M2 macrophages' anti-inflammatory potency. We demonstrated that the modified macrophages could significantly attenuate the inflammatory progress of Complete Freund's adjuvant (CFA)-induced arthritis and collagen-induced arthritis in rodents. Here, we provide the first evidence that a modified macrophage population could ectopically express Col II and control the progress of arthritis in animals.


Asunto(s)
Artritis Experimental , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Animales , Humanos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Factor Estimulante de Colonias de Macrófagos/farmacología , Factor Estimulante de Colonias de Macrófagos/metabolismo , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Leucocitos Mononucleares/metabolismo , Macrófagos/metabolismo , Factores Estimulantes de Colonias/metabolismo , Artritis Experimental/metabolismo
4.
Artículo en Inglés | MEDLINE | ID: mdl-35162891

RESUMEN

OBJECTIVES: This study aimed to assess the effectiveness of practicing acupressure on the Shenmen and Neiguan acupoints with a view to reduce anxiety and improve the comfort and physical health of patients undergoing thoracoscopic surgery. METHODS: A total of 100 hospitalized patients undergoing thoracoscopic surgery were assigned randomly into the experimental (n = 49) and control groups (n = 51). Subjects in the experimental group received routine care plus acupressure on the Shenmen and Neiguan acupoints, while those in the control group received regular routine care. The data were collected using demographic information, physical and surgical data, the Visual Analog Scale (VAS)-A, the State-Trait Anxiety Inventory Y Form (STAI-Y1), and Shortened General Comfort Questionnaire scores. The linear mixed model was used to examine the influences of acupressure on VAS-A and STAI-Y1 scores at different time points before and after the surgery to observe group-by-time interactions. RESULTS: The mean age of the subjects was 60.97 years. All subjects had mild-to-moderate anxiety after surgery and showed a statistically significant decline in regression coefficients on the first and second days after the intervention (ß = -11.61, p = 0.002; ß = -18.71, p < 0.001). Similarly, for STAI-YI scores, the data showed a significant difference in the pre-test and post-test interactions between the two groups (ß = 4.72, p = 0.031). Conversely, acupressure did not have a statistically significant difference on comfort (F = 2.953, p = 0.057). Compared with the control subjects, the experimental subjects used less morphine and developed side effects less frequently (p < 0.01). They were also able to get out of bed after surgery 163.79 min earlier (p < 0.05). CONCLUSIONS: Acupressure is a simple and easy-to-practice treatment. Acupressure on the Shenmen and Neiguan acupoints reduces anxiety and improves recovery in patients after undergoing thoracoscopic surgery.


Asunto(s)
Acupresión , Ansiedad/prevención & control , Trastornos de Ansiedad , Humanos , Persona de Mediana Edad , Toracoscopía
5.
J Nurs Scholarsh ; 54(4): 411-421, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-34854214

RESUMEN

PURPOSE: More than 86% patients experience moderate to severe pain after thoracoscopic surgery. A combination of diverse nonpharmacological pain relief methods is a developing trend for pain management. The purpose of this study was to explore the effect of acupressure in reducing pain after thoracoscopic surgery. DESIGN: A Randomized controlled study with purpose sampling was used for this study. Patients who underwent thoracoscopic surgery at a medical center in central Taiwan were enrolled. Study data was collected from September 2020 to April 2021 after the approval of the institutional review board. A total of 100 participants were randomized into two groups (49 and 51 in the experimental and control groups, respectively). METHODS: Participants in the experimental group received acupressure at the Neiguan (PC6) and Shenmen (HT7) acupoints thrice a day for 2 days, whereas those in the control group received routine treatment and did not receive acupressure. The measurement included questionnaires for the collection of general information, physiological information, and disease rating scale. The Visual Analogue Scale-Pain (VAS-P) was used to measure the severity of pain. SPSS statistical software was used for data analysis. Independent sample t-test and chi-squared test were used for descriptive statistics, and paired t-test and linear mixed model were used to examine the effect of acupressure in alleviating pain. FINDINGS: After acupressure intervention, the pain score of the experimental group was lower than that of the control group, and this difference was significant ß = 17.76, p < 0.001 on day 1 after intervention; ß = 19.80, p < 0.001 on day 2 after intervention. The postoperative pain score in the experimental group on day 2 after intervention was significantly lower than that in the control group (t = 2.039, p = 0.044). After the subjects received acupressure, pain index significantly decreased after considering the interaction between time and group (p < 0.001). Regardless of the type of surgery, there were significant differences in pain index when the interaction between time and group was considered (p < 0.001). CONCLUSIONS: This study provided an experimental basis that acupressure can help in pain management in patients after thoracoscopic surgery, and the pain relief results become more significant as the duration of intervention increases. CLINICAL RELEVANCE: Acupressure is effective in relieving postoperative pain in any type of thoracoscopic surgery. Nurses can use acupressure to help control pain in patients after thoracoscopic surgery.


Asunto(s)
Acupresión , Acupresión/métodos , Humanos , Manejo del Dolor/métodos , Dimensión del Dolor , Dolor Postoperatorio/terapia , Toracoscopía
6.
Neurosurgery ; 80(3): 475-488, 2017 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-28362972

RESUMEN

Background: Axon degeneration leads to cytoskeletal disassembly, metabolism imbalance, and mitochondrial dysfunction during neurodegeneration or nerve injury. Objective: In this study, we assess the possibility of mitigating axon degeneration by local injection of mitochondria in a crushed sciatic nerve. Methods: Sciatic nerve explants cocultured with mitochondria were assessed for the optimal dosage in local injection and nerve regeneration potential. The left sciatic nerve was crushed in Sprague-Dawley rats and then local injection of mitochondria into the distal end of the injured nerve was conducted for further assessment. Results: Mitochondrial coculture attenuated cytoskeletal loss and oxidative stress in isolated nerve explants. In Vivo analyses also showed that mitochondrial transplantation improved animal neurobehaviors, electrophysiology of nerve conduction, and muscle activities. Mitochondria injection significantly attenuated the oxidative stress and increased the expression of neurotrophic factors both in injured nerves and denervated muscles, as well as restored muscular integrity, and increased the pool of muscular progenitor cells and total muscle weight. Conclusion: Mitochondria injection can protect injured nerves from axonal degeneration both in Vitro and in Vivo. This improvement was accompanied with the expression of neurotrophic factors as well as the reduction of oxidative stress, which may account for the functional recovery of both injured nerves and denervated muscles.


Asunto(s)
Axones/patología , Mitocondrias/metabolismo , Compresión Nerviosa , Degeneración Nerviosa/prevención & control , Traumatismos de los Nervios Periféricos/patología , Recuperación de la Función/fisiología , Nervio Ciático/lesiones , Neuropatía Ciática/patología , Animales , Axones/metabolismo , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/patología , Regeneración Nerviosa/fisiología , Traumatismos de los Nervios Periféricos/metabolismo , Ratas , Ratas Sprague-Dawley , Nervio Ciático/metabolismo , Nervio Ciático/patología , Neuropatía Ciática/metabolismo
7.
Psychopharmacology (Berl) ; 233(4): 661-72, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26554386

RESUMEN

RATIONALE: Repeated administration of methamphetamine (Meth) induces behavioral sensitization which is characterized by a progressive increase in locomotor response after each injection. Previous studies have shown that Mu opioid receptors (MORs) can regulate Meth-mediated behavioral sensitization. However, the reported interactions are controversial; systemic activation of MORs either enhanced or suppressed Meth sensitization. It is possible that alteration of Meth sensitization after systemic administration of MOR ligands reflects the sum of distinct MOR reactions in multiple brain regions. OBJECTIVES: The purpose of the present study was to examine the actions of MORs on Meth sensitization after regionally selective overexpression of human MOR through an AAV6-based gene delivery system. METHOD: We demonstrated that adeno-associated virus (AAV)-MOR increased MOR immunoreactivity and binding in vitro. AAV-MOR or AAV-green fluorescent protein (GFP) was injected into the nucleus accumbens (NAc) or ventral tegmental area (VTA) of adult mice. Two weeks after viral infection, animals received Meth or saline for five consecutive days. Locomotor behavior and striatal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) level were determined. RESULTS: Repeated administration of Meth progressively increased locomotor activity; this sensitization reaction was attenuated by intra-NAc AAV-MOR microinjections. Infusion of AAV-MOR to VTA enhanced Meth sensitization. AAV-MOR significantly enhanced DA levels in VTA after VTA infection but reduced DOPAC/DA turnover in the NAc after NAc injection. CONCLUSION: Our data suggest a differential modulation of Meth sensitization by overexpression of MOR in NAc and VTA. Regional manipulation of MOR expression through AAV may be a novel approach to control Meth abuse and psychomimetic activity.


Asunto(s)
Metanfetamina/administración & dosificación , Actividad Motora/efectos de los fármacos , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Receptores Opioides mu/biosíntesis , Área Tegmental Ventral/efectos de los fármacos , Área Tegmental Ventral/metabolismo , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Regulación de la Expresión Génica , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Microinyecciones , Actividad Motora/fisiología
8.
Cell Transplant ; 25(5): 913-27, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26555763

RESUMEN

Transferring exogenous mitochondria has therapeutic effects on damaged heart, liver, and lung tissues. Whether this protective effect requires the symbiosis of exogenous mitochondria in host cells remains unknown. Here xenogenic mitochondria derived from a hamster cell line were applied to ischemic rat brains and rat primary cortical neurons. Isolated hamster mitochondria, either through local intracerebral or systemic intra-arterial injection, significantly restored the motor performance of brain-ischemic rats. The brain infarct area and neuronal cell death were both attenuated by the exogenous mitochondria. Although internalized mitochondria could be observed in neurons and astrocytes, the low efficacy of mitochondrial internalization could not completely account for the high rate of rescue of the treated neural cells. We further illustrated that disrupting electron transport or ATPase synthase in mitochondria significantly attenuated the protective effect, suggesting that intact respiratory activity is essential for the mitochondrial potency on neural protection. These results emphasize that nonsymbiotic extracellular mitochondria can provide an effective cell defense against acute injurious ischemic stress in the central nervous system.


Asunto(s)
Isquemia Encefálica/terapia , Infarto de la Arteria Cerebral Media/terapia , Mitocondrias/trasplante , Neuroprotección/fisiología , Fármacos Neuroprotectores/uso terapéutico , Trasplante Heterólogo , Animales , Encéfalo/patología , Isquemia Encefálica/patología , Muerte Celular/fisiología , Línea Celular , Supervivencia Celular , Cricetinae , Transporte de Electrón/fisiología , Infarto de la Arteria Cerebral Media/patología , Inyecciones Intraarteriales , Masculino , Neuronas/citología , Ratas , Ratas Sprague-Dawley
9.
Artículo en Inglés | MEDLINE | ID: mdl-23606876

RESUMEN

The present study was conducted to evaluate the effect of electroacupuncture-(EAc-) induced antinociception (EAA) at different currents and frequencies in rat spinal cord. We found that naloxone (0.05 µ g i.t.) blocked EAA at different frequencies. Naltrindole (0.05 µ g i.t.) blocked EAA on the 7th day after EAc of 100 Hz. 5,7-Dihydroxytryptamine (100 µ g i.t.) significantly inhibited EAA at different frequencies on the 7th day after EAc. Pindobind (0.5 µ g i.t.), a 5-HT1A antagonist, notably attenuated EAA at different frequencies. Ketanserin (0.5 µ g i.t.), inhibited EEA at a lower frequency (<10 Hz) than at a higher frequency (100 Hz). LY-278584 (0.5 µ g i.t.) significantly inhibited EAA at a higher frequency (100 Hz) on the 7th day after EAc. The direction of effect of 8-OH-DPAT, on EAA was dependent on dosage. It had an inhibitory effect at a low dose (0.5 µ g i.t.) and a high frequency (100 Hz) but enhanced EAA at a higher dose at lower frequencies (<10 Hz). DOI (10 µ g, i.t.), did not affect EAA. These data indicate that the mechanism of EAA involves opioid receptors, and the serotonergic system, particularly, µ -, δ -opioid and 5-HT1A, 5-HT3 receptors and it is also dependent on the EAc frequency.

11.
Ann Neurol ; 65(5): 520-30, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19475672

RESUMEN

OBJECTIVE: Cerebral ischemia can activate endogenous reparative processes, such as proliferation of endogenous neural progenitor cells (NPCs) in the subventricular zone (SVZ). Most of these new cells die shortly after injury. The purpose of this study was to examine a novel strategy for treatment of stroke at 1 week after injury by enhancing the survival of ischemia-induced endogenous NPCs in SVZ. METHODS: Adult rats were subjected to a 90-minutes middle cerebral artery occlusion. A p53 inhibitor pifithrin-alpha (PFT-alpha) was administered to stroke rats from days 6 to 9 after middle cerebral artery occlusion. Locomotor behavior was measured using an activity chamber. Proliferation, survival, migration, and differentiation of endogenous NPCs were examined using quantitative reverse transcription polymerase chain reaction, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, and immunohistochemistry. RESULTS: PFT-alpha enhanced functional recovery as assessed by a significant increase in multiple behavioral measurements. Delayed PFT-alpha treatment had no effect on the cell death processes in the lesioned cortical region. However, it enhanced the survival of SVZ progenitor cells, and promoted their proliferation and migration. PFT-alpha inhibited the expression of a p53-dependent proapoptotic gene, termed PUMA (p53-upregulated modulator of apoptosis), within the SVZ of stroke animals. The enhancement of survival/proliferation of NPCs was further found in SVZ neurospheres in tissue culture. PFT-alpha dose-dependently increased the number and size of new neurosphere formation. INTERPRETATION: Delayed treatment with a p53 inhibitor PFT-alpha is able to modify stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals.


Asunto(s)
Benzotiazoles/farmacología , Encéfalo/efectos de los fármacos , Infarto de la Arteria Cerebral Media/patología , Recuperación de la Función/efectos de los fármacos , Tolueno/análogos & derivados , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Células Madre Adultas/efectos de los fármacos , Análisis de Varianza , Animales , Encéfalo/patología , Encéfalo/fisiopatología , Bromodesoxiuridina/metabolismo , Diferenciación Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Ventrículos Cerebrales/patología , Modelos Animales de Enfermedad , Embrión de Mamíferos , Proteína Ácida Fibrilar de la Glía/metabolismo , Etiquetado Corte-Fin in Situ/métodos , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Antígeno Nuclear de Célula en Proliferación/metabolismo , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Tolueno/farmacología , Regulación hacia Arriba/efectos de los fármacos
12.
J Comp Neurol ; 515(1): 116-24, 2009 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-19399876

RESUMEN

Mesencephalic astrocyte-derived neurotrophic factor (MANF), also known as arginine-rich, mutated in early stage of tumors (ARMET), is a secreted protein that reduces endoplasmic reticulum (ER) stress. Previous studies have shown that MANF mRNA expression and protein levels are increased in the cerebral cortex after brain ischemia, a condition that induces ER stress. The function of MANF during brain ischemia is still not known. The purpose of this study was to examine the protective effect of MANF after ischemic brain injury. Recombinant human MANF was administrated locally to the cerebral cortex before a 60-min middle cerebral artery occlusion (MCAo) in adult rats. Triphenyltetrazolium chloride (TTC) staining indicated that pretreatment with MANF significantly reduced the volume of infarction at 2 days after MCAo. MANF also attenuated TUNEL labeling, a marker of cell necrosis/apoptosis, in the ischemic cortex. Animals receiving MANF pretreatment demonstrated a decrease in body asymmetry and neurological score as well as an increase in locomotor activity after MCAo. Taken together, these data suggest that MANF has neuroprotective effects against cerebral ischemia, possibly through the inhibition of cell necrosis/apoptosis in cerebral cortex.


Asunto(s)
Infarto Encefálico/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Degeneración Nerviosa/tratamiento farmacológico , Proteínas del Tejido Nervioso/uso terapéutico , Recuperación de la Función/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Encéfalo/metabolismo , Encéfalo/fisiopatología , Infarto Encefálico/metabolismo , Infarto Encefálico/fisiopatología , Citoprotección/efectos de los fármacos , Citoprotección/fisiología , Modelos Animales de Enfermedad , Humanos , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/fisiopatología , Indicadores y Reactivos , Masculino , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Necrosis/tratamiento farmacológico , Necrosis/metabolismo , Necrosis/fisiopatología , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/fisiopatología , Factores de Crecimiento Nervioso , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/farmacología , Recuperación de la Función/fisiología , Coloración y Etiquetado , Sales de Tetrazolio , Resultado del Tratamiento
13.
FASEB J ; 23(6): 1958-68, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19218497

RESUMEN

Astaxanthin (ATX) is a dietary carotenoid of crustaceans and fish that contributes to their coloration. Dietary ATX is important for development and survival of salmonids and crustaceans and has been shown to reduce cardiac ischemic injury in rodents. The purpose of this study was to examine whether ATX can protect against ischemic injury in the mammalian brain. Adult rats were injected intracerebroventricularly with ATX or vehicle prior to a 60-min middle cerebral artery occlusion (MCAo). ATX was present in the infarction area at 70-75 min after onset of MCAo. Treatment with ATX, compared to vehicle, increased locomotor activity in stroke rats and reduced cerebral infarction at 2 d after MCAo. To evaluate the protective mechanisms of ATX against stroke, brain tissues were assayed for free radical damage, apoptosis, and excitoxicity. ATX antagonized ischemia-mediated loss of aconitase activity and reduced glutamate release, lipid peroxidation, translocation of cytochrome c, and TUNEL labeling in the ischemic cortex. ATX did not alter physiological parameters, such as body temperature, brain temperature, cerebral blood flow, blood gases, blood pressure, and pH. Collectively, our data suggest that ATX can reduce ischemia-related injury in brain tissue through the inhibition of oxidative stress, reduction of glutamate release, and antiapoptosis. ATX may be clinically useful for patients vulnerable or prone to ischemic events.


Asunto(s)
Lesiones Encefálicas/tratamiento farmacológico , Isquemia Encefálica/prevención & control , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Aconitato Hidratasa/metabolismo , Animales , Conducta Animal/efectos de los fármacos , Lesiones Encefálicas/patología , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/patología , Circulación Cerebrovascular , Crustáceos , Citocromos c/metabolismo , Dieta , Ácido Glutámico/metabolismo , Humanos , Etiquetado Corte-Fin in Situ , Peroxidación de Lípido , Masculino , Estructura Molecular , Actividad Motora/efectos de los fármacos , Fármacos Neuroprotectores/química , Ratas , Ratas Sprague-Dawley , Flujo Sanguíneo Regional , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Xantófilas/química , Xantófilas/farmacología , Xantófilas/uso terapéutico
14.
J Neurosci Res ; 87(2): 545-55, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18803283

RESUMEN

Retinoic acid (RA), a biologically active derivative of vitamin A, has protective effects against damage caused by H(2)O(2) or oxygen-glucose deprivation in mesangial and PC12 cells. In cultured human osteosarcoma cells, RA enhances the expression of bone morphogenetic protein-7 (BMP7), a trophic factor that reduces ischemia- or neurotoxin-mediated neurodegeneration in vivo. The purpose of this study is to examine whether RA reduces ischemic brain injury through a BMP7 mechanism. We found that intracerebroventricular administration of 9-cis-retinoic acid (9cRA) enhanced BMP7 mRNA expression, detected by RT-PCR, in rat cerebral cortex at 24 hr after injection. Rats were also subjected to transient focal ischemia induced by ligation of the middle cerebral artery (MCA) at 1 day after 9cRA injection. Pretreatment with 9cRA increased locomotor activity and attenuated neurological deficits 2 days after MCA ligation. 9cRA also reduced cerebral infarction and TUNEL labeling. These protective responses were antagonized by the BMP antagonist noggin given 1 day after 9cRA injection. Taken together, our data suggest that 9cRA has protective effects against ischemia-induced injury, and these effects involve BMPs.


Asunto(s)
Proteína Morfogenética Ósea 7/efectos de los fármacos , Isquemia Encefálica/tratamiento farmacológico , Fármacos Neuroprotectores/administración & dosificación , Tretinoina/administración & dosificación , Alitretinoína , Animales , Proteína Morfogenética Ósea 7/biosíntesis , Isquemia Encefálica/complicaciones , Isquemia Encefálica/patología , Proteínas Portadoras/farmacología , Expresión Génica , Etiquetado Corte-Fin in Situ , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Infarto de la Arteria Cerebral Media/etiología , Infarto de la Arteria Cerebral Media/patología , Inyecciones Intraventriculares , Masculino , Actividad Motora/efectos de los fármacos , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Recuperación de la Función/efectos de los fármacos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
15.
Neurosci Lett ; 442(1): 15-8, 2008 Sep 05.
Artículo en Inglés | MEDLINE | ID: mdl-18598737

RESUMEN

Previous studies have indicated that methamphetamine (MA) potentiates neurodegeneration induced by ischemia in brain. We, and others, have reported that bone morphogenetic protein 7 (BMP7) is protective against MA and ischemic brain injury. The purpose of this study is to examine whether BMP7 reduces synergistic injury induced by both MA and cerebral ischemia. Adult CD-1 mice were treated with MA (4x 10mg/kg, each dose 2h apart) or saline. Using the quantitative real time polymerase chain reaction, we found that MA suppressed the expression of BMP7 mRNA in the cerebral cortex 1 day after injection. Ischemic and reperfusional injuries were introduced by ligation of the right middle cerebral artery for 90min after MA injection. Animals were sacrificed for caspase-3/7 activity assay and tri-phenyl-tetrazolium chloride staining at 1h and 2 days after reperfusion, respectively. Cerebral infarction and caspase-3/7 activity were enhanced in the stroke animals pretreated with MA; both responses were attenuated by pretreatment with BMP7. In conclusion, our data suggest that MA facilitates cerebral infarction after ischemia possibly mediated, in part, through the suppression of BMP7.


Asunto(s)
Proteínas Morfogenéticas Óseas/metabolismo , Isquemia Encefálica/patología , Dopaminérgicos/toxicidad , Expresión Génica/efectos de los fármacos , Metanfetamina/toxicidad , Factor de Crecimiento Transformador beta/metabolismo , Animales , Proteína Morfogenética Ósea 7 , Proteínas Morfogenéticas Óseas/administración & dosificación , Caspasa 3/efectos de los fármacos , Caspasa 7/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Ratones , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Crecimiento Transformador beta/administración & dosificación
16.
Acta Neurol Taiwan ; 14(1): 9-15, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15835283

RESUMEN

Holmes tremor is a rare symptomatic slow tremor in the proximal parts of the limbs. It may be present at rest or maintenance of a posture, or during the movement of the affected limb. We describe herein three patients of Holmes tremor with possible etiologies of brainstem infarction and head injury. The intervals between the causal events and the appearance of tremor range from 1 month to 12 months. Magnetic resonance imaging studies reveal hypertrophy of the inferior olivary nucleus in all of the three patients, although only one of them has palatal myoclonus. The surface electromyographic recordings reveal characteristic slow oscillation with frequencies of 3.5 to 4.2 Hz. These features suggest that perturbation of the dentato-rubral-olivary circuitry may play a pivotal role for the generation of Holmes tremor. However, no tight correlation is observed between the presence of inferior olivary nuclear hypertrophy and the appearance of symptomatic palatal myoclonus in the current report.


Asunto(s)
Temblor/diagnóstico , Adulto , Electromiografía , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Mioclonía/etiología , Núcleo Olivar/patología
17.
Eur Neurol ; 49(1): 53-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12464719

RESUMEN

The Clock-Drawing Test (CDT) has been used to screen for Alzheimer's disease (AD) as a supplement to cognitive tests that focus on memory impairment. We examined a comprehensive scoring system of the CDT in screening of AD in a Chinese population and derived a simplified scoring system. All 403 (144 AD and 259 nondemented) subjects were administered the CDT, including both the drawing part (CDT-D) and the copying part (CDT-C). The Cognitive Abilities Screening Instrument and the Clinical Dementia Rating were also administered. Stepwise discriminant analysis was used to develop a simplified CDT scoring system. The optimal CDT cutoff scores (CDT-D: 10/11; CDT-C: 12/13) show intermediate sensitivity (CDT-D: 66.7%; CDT-C: 51.4%) and specificity (CDT-D: 74.5%; CDT-C: 74.1%). The simplified 3-item CDT scoring system, with a cutoff score of 2/3, has a sensitivity of 72.9% and a specificity of 65.6%; it can be used as a quick test for AD screening.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Tamizaje Masivo , Recuerdo Mental , Pruebas Neuropsicológicas/estadística & datos numéricos , Desempeño Psicomotor , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/psicología , Comparación Transcultural , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valores de Referencia , Taiwán
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA